SUPN - Supernus Pharmaceuticals, Inc.

Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD

ROCKVILLE, Md., July 14, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, celebrates the five-year anniversary of the U.S. Food and Drug Administration (FDA) approval of Qelbree (viloxazine extended-release capsules) for attention-deficit/hyperactivity disorder (ADHD). Since its initial approval for pediatric (6 to 17 years) ADHD in April 2021, and subsequent approval for adults in April 2022, Qelbree has served as a valuable option for the nearly 16 million adults and 7 million children and teens living with ADHD in the U.S.,1,2 showcasing Supernus' 25+ year legacy in ADHD research.

Jul 14, 2026 04:30 AM • globenewswire.com

Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength?

Supernus (SUPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Jul 09, 2026 06:25 AM • zacks.com

Supernus Pharmaceuticals to Participate in June Investor Conferences

ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following June investor conferences:

May 27, 2026 12:30 PM • globenewswire.com

Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 12, 2026 09:10 PM • seekingalpha.com

What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year

Supernus Pharmaceuticals delivers specialty therapies for CNS disorders, targeting healthcare providers and specialty pharmacies nationwide.

May 12, 2026 08:50 AM • fool.com

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

ROCKVILLE, Md. , May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.

May 06, 2026 01:00 PM • globenewswire.com

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas, NV.

May 06, 2026 01:00 PM • globenewswire.com

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript

May 05, 2026 06:21 PM • seekingalpha.com

Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

May 05, 2026 04:01 PM • zacks.com

Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.42 per share a year ago.

May 05, 2026 03:10 PM • zacks.com

Supernus Announces First Quarter 2026 Financial Results

ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter 2026 and associated Company developments.

May 05, 2026 12:05 PM • globenewswire.com

Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs

Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.

Apr 29, 2026 07:21 AM • zacks.com

Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026

ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report first quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026.

Apr 22, 2026 12:15 PM • globenewswire.com

Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Supernus Pharmaceuticals stock on March 3rd. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account. Representative

Apr 13, 2026 01:42 AM • defenseworld.net

Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Cross Above 200-Day Moving Average – Should You Sell?

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report)'s share price crossed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $49.66 and traded as high as $51.06. Supernus Pharmaceuticals shares last traded at $50.96, with a volume of 873,941 shares. Analysts Set

Apr 07, 2026 11:43 PM • defenseworld.net

Supernus Pharmaceuticals, Inc. $SUPN Stock Holdings Lowered by JPMorgan Chase & Co.

JPMorgan Chase and Co. trimmed its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 45.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 171,285 shares of the specialty pharmaceutical company's stock after selling 143,816 shares during the period. JPMorgan Chase

Mar 30, 2026 01:44 AM • defenseworld.net

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives $62.17 Consensus PT from Brokerages

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) has received a consensus rating of "Hold" from the seven brokerages that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The

Mar 29, 2026 11:32 PM • defenseworld.net

Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year

A Supernus Pharmaceuticals executive reported the sale of 107,250 Common Stock shares over three days for a total value of about $5.4 million. Bhatt reported holding 17,044 shares of directly owned common stock after the transactions.

Mar 27, 2026 02:41 PM • fool.com

Frederick Hudson Sells 5,369 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) Director Frederick Hudson sold 5,369 shares of the business's stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $50.61, for a total transaction of $271,725.09. Following the completion of the sale, the director directly owned 60,413 shares in the

Mar 18, 2026 01:00 AM • defenseworld.net

Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 11, 2026 11:52 AM • seekingalpha.com

Supernus Pharmaceuticals (SUPN) PT Raised to $65 at TD Cowen

$65.00 (was $57.58)

Craig-Hallum

Feb 25, 2026 09:19 AM • StreetInsider

Supernus price target raised to $55 from $50 at Stifel

$55.00 (was $49.28)

Annabel Samimy · Stifel Nicolaus

Dec 19, 2025 07:50 AM • TheFly

Supernus upgraded to Overweight from Neutral at Piper Sandler

$65.00 (was $48.00)

Piper Sandler

Oct 08, 2025 07:34 PM • TheFly

Supernus price target raised to $63 from $46 at Cantor Fitzgerald

$63.00 (was $47.41)

Cantor Fitzgerald

Sep 30, 2025 08:42 AM • TheFly

Supernus price target raised to $40 from $36 at Piper Sandler

$40.00 (was $45.12)

Piper Sandler

Aug 29, 2025 06:36 AM • TheFly

Supernus upgraded to Overweight from Neutral at Cantor Fitzgerald

$42.00 (was $33.45)

Cantor Fitzgerald

Jul 29, 2025 04:08 PM • TheFly

Piper downgrades Supernus to Neutral on slower Qelbree growth

$36.00 (was $33.49)

David Amsellem · Piper Sandler

Sep 11, 2024 12:55 AM • TheFly

Piper Sandler Reiterates Overweight Rating on Supernus Pharmaceuticals (SUPN)

$41.00 (was $27.84)

David Amsellem · Piper Sandler

May 24, 2024 03:28 AM • StreetInsider

Jefferies on Supernus (SUPN): 'We expect a -5-10% stock reaction after the FDA's rejection of SPN-830'

$40.00 (was $32.27)

Irene Buhalo · Jefferies

Apr 08, 2024 06:10 AM • StreetInsider

Stifel on Supernus Pharmaceuticals (SUPN): 'SPN-830 Approval Delayed Again, but Near-Term Impact Relatively Minor'

$38.00 (was $32.27)

Annabel Samimy · Stifel Nicolaus

Apr 08, 2024 06:09 AM • StreetInsider